Details for Patent: 7,754,731
✉ Email this page to a colleague
Which drugs does patent 7,754,731 protect, and when does it expire?
Patent 7,754,731 protects ISENTRESS, DUTREBIS, and ISENTRESS HD, and is included in four NDAs.
Protection for ISENTRESS has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has forty-six patent family members in thirty-five countries.
Summary for Patent: 7,754,731
| Title: | Potassium salt of an HIV integrase inhibitor |
| Abstract: | Potassium salts of Compound A and methods for their preparation are disclosed, wherein Compound A is of formula: ##STR00001## Compound A is an HIV integrase inhibitor useful for treating or prophylaxis of HIV infection, for delaying the onset of AIDS, and for treating or prophylaxis of AIDS. |
| Inventor(s): | Belyk; Kevin M. (Somerset, NJ), Morrison; Henry G. (Simi Valley, CA), Mahajan; Amar J. (Piscataway, NJ), Kumke; Daniel J. (Colts Neck, NJ), Tung; Hsien-Hsin (Edison, NJ), Wai; Lawrence (Scotch Plains, NJ), Pruzinsky; Vanessa (Metuchen, NJ) |
| Assignee: | Merck Sharp & Dohme Corp. (Rahway, NJ) |
| Application Number: | 11/293,678 |
|
Patent Claim Types: see list of patent claims | Compound; Composition; Use; Process; |
Drugs Protected by US Patent 7,754,731
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Msd Sub Merck | ISENTRESS | raltegravir potassium | POWDER;ORAL | 205786-001 | Dec 20, 2013 | RX | Yes | Yes | 7,754,731*PED | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Msd Sub Merck | ISENTRESS | raltegravir potassium | TABLET, CHEWABLE;ORAL | 203045-001 | Dec 21, 2011 | RX | Yes | No | 7,754,731*PED | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Msd Sub Merck | ISENTRESS | raltegravir potassium | TABLET, CHEWABLE;ORAL | 203045-002 | Dec 21, 2011 | RX | Yes | Yes | 7,754,731*PED | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Merck Sharp Dohme | DUTREBIS | lamivudine; raltegravir potassium | TABLET;ORAL | 206510-001 | Feb 6, 2015 | DISCN | No | No | 7,754,731*PED | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Msd Sub Merck | ISENTRESS | raltegravir potassium | TABLET;ORAL | 022145-001 | Oct 12, 2007 | RX | Yes | Yes | 7,754,731*PED | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Msd Sub Merck | ISENTRESS HD | raltegravir potassium | TABLET;ORAL | 022145-002 | May 26, 2017 | RX | Yes | Yes | 7,754,731*PED | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 7,754,731
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 052034 | ⤷ Subscribe | |||
| Argentina | 101429 | ⤷ Subscribe | |||
| Austria | E518844 | ⤷ Subscribe | |||
| Austria | E534645 | ⤷ Subscribe | |||
| Australia | 2005311671 | ⤷ Subscribe | |||
| Brazil | PI0518760 | ⤷ Subscribe | |||
| Canada | 2588398 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
